JBF Capital’s Prime Medicine PRME Stock Holding History

JBF Capital’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-188,900	Closed	-$1.05M	–	91
2025 Q3	$1.05M	Buy	+188,900	New	+$767K	0.15%	37

Other funds holding PRME

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

JBF Capital's PRME Position: Q4 2025 in Review

JBF Capital sold out of Prime Medicine (PRME) in Q4 2025, closing a stake of 188,900 shares — an estimated $1.05M sold.

JBF Capital first reported a position in PRME in Q3 2025 and held it in 1 quarter. The position peaked at $1.05M in Q3 2025. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

JBF Capital reported no remaining Prime Medicine position as of Q4 2025 after selling out during the quarter.
JBF Capital sold 188,900 Prime Medicine shares in Q4 2025, an estimated $1.05M.
JBF Capital first reported a position in Prime Medicine in Q3 2025 and held it in 1 quarter.
JBF Capital's Prime Medicine position peaked at $1.05M in Q3 2025.
183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on JBF Capital's 13F filing for Q4 2025, filed 12 Feb 2026.